The advisory committee on immunization practices' interim recommendation for use of Pfizer-Biontech Covid-19 vaccine in children aged 5­11 years: United States, november 2021

Woodworth, Kate R; Moulia, Danielle; Collins, Jennifer P; Hadler, Stephen C; Jones, Jefferson M; Reddy, Sujan C; Chamberland, Mary; Campos-Outcalt, Doug; Morgan, Rebecca L; Brooks, Oliver; Talbot, H. Keipp; Lee, Grace M; Bell, Beth P; Daley, Matthew F; Mbaeyi, Sarah; Dooling, Kathleen; Oliver, Sara E.
MMWR recomm. rep ; 70(45): 1579-1583, Nov. 12, 2022. tab
Artículo en Inglés | BIGG | ID: biblio-1397007

Documentos relacionados

  1. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.
  2. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
  3. Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
  4. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
  5. Slow Waning of Antibodies Following BNT162b2 as a Third Dose in Adults Who Had Previously Received 2 Doses of Inactivated Vaccine.
  6. COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation.
  7. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
  8. Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. Reply.
  9. Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
  10. Covid-19 Vaccine Protection among Children and Adolescents in Qatar.